Search

Our findings define PTPN2 as a target for bolstering T-cell-mediated anti-tumour immunity and CAR T-cell therapy against solid tumours.

We established a pipeline to assess the effects of epigenetic modifiers on CD8+ T cell proliferation, differentiation, and efficacy in a preclinical melanoma model

Results support the emerging concept that CD103+ CD8+ tissue‐resident memory T cells are key mediators of cancer surveillance

Whole genome sequencing of poor and exceptional survivors identified a gain in Chromosome 19 that was exclusive to the exceptional survivors

These findings reveal a central role of the DG receptor, not only as a structural element, but also as a critical factor promoting mesenchymal-like GBM

Our current Research Topic highlights the complexity of the relationship between the skin, immune system and skin cancer

Our results identify a pretreatment tumor microenvironment that predicts response to immune checkpoint blockade, which can be therapeutically attained

These findings suggest that tumor cells employ multiple epigenetic and genetic mechanisms to evade immune control

Our findings provide insight into the immune cell populations important for maintaining long-term tumour dormancy in peripheral tissues

In this review, we discuss the different subsets of tumor-infiltrating dendritic cells and their role in anti-tumor immunity